PGC-1α

PGC-1α製品

  • All (4)
  • PGC-1α阻害剤 (1)
  • PGC-1α活性剤(3)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S1168 Valproic Acid sodium Valproic Acid sodium is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.
J Exp Clin Cancer Res, 2024, 43(1):152
J Immunother Cancer, 2024, 12(11)e009805
Front Pharmacol, 2024, 15:1534772
Sodium-valproate-S116801W0120110511.gif
S3944 VPA (Valproic acid) VPA (Valproic acid) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.
Cell, 2025, S0092-8674(25)00406-4
Nat Commun, 2025, 16(1):8267
Stem Cell Res Ther, 2025, 16(1):426
S7447 ZLN005 ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
bioRxiv, 2025, 2025.01.10.632395
Nephrology (Carlton), 2024, 29(12):858-872
Front Immunol, 2023, 14:1089905
ZLN005-S744701W0220160914.gif
S8528 SR-18292 SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.
PLoS One, 2025, 20(2):e0310908
Cell Chem Biol, 2024, 31(10):1772-1786.e5
JCI Insight, 2023, 8(17)e170513
S8528 SR-18292 SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.
PLoS One, 2025, 20(2):e0310908
Cell Chem Biol, 2024, 31(10):1772-1786.e5
JCI Insight, 2023, 8(17)e170513
S1168 Valproic Acid sodium Valproic Acid sodium is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.
J Exp Clin Cancer Res, 2024, 43(1):152
J Immunother Cancer, 2024, 12(11)e009805
Front Pharmacol, 2024, 15:1534772
Sodium-valproate-S116801W0120110511.gif
S3944 VPA (Valproic acid) VPA (Valproic acid) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.
Cell, 2025, S0092-8674(25)00406-4
Nat Commun, 2025, 16(1):8267
Stem Cell Res Ther, 2025, 16(1):426
S7447 ZLN005 ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
bioRxiv, 2025, 2025.01.10.632395
Nephrology (Carlton), 2024, 29(12):858-872
Front Immunol, 2023, 14:1089905
ZLN005-S744701W0220160914.gif